Table 3 Univariate analysis of PFS and OS

Sex

0.168

0.250

 Male

8.00, (6.01–9.99)

30.00, (24.44–35.56)

 Female

11.50, (10.16–12.84)

38.00, (22.88–53.13)

Age

0.790

0.530

  ≤ 60 years old

10.40, (1.20–8.04)

30.00, (26.35–33.65)

  > 60 years old

9.50, (6.96–12.04)

32.50, (25.86–39.14)

Body mass index

0.564

0.345

  ≤ 25 kg/m²

8.50, (5.79–11.21)

30.00, (26.87–33.14)

  > 25 kg/m²

10.40, (9.28–11.52)

38.00, (25.067–50.93)

Smoke abuse

0.751

0.133

 Yes

9.50, (6.87–12.13)

30.00, (27.61–32.38)

 No

10.40, (8.64–12.16)

39.00, (27.19–50.81)

Serum CEA

0.048

0.004

  ≤ 15 ng/ml

11.50, (10.26–12.75)

39.00, (30.30–47.69)

  > 15 ng/ml

7.50, (4.84–10.16)

28.30, (22.85–33.75)

Primary tumor site

0.151

0.201

 Colon

11.00, (9.29–12.71)

32.50, (29.50–35.49)

 Rectum

8.00, (5.65–10.35)

30.00, (27.90–32.10)

Pathological classification

0.015

0.000

 Low differentiated

6.30, (4.45–8.15)

23.00, (20.17–25.84)

 Middle-High differentiated

11.40, (9.77–13.03)

39.00, (30.54–47.46)

TNM stage

0.001

0.000

 Stage I-III

11.50, (11.10–11.90)

39.00, (31.95–46.05)

 Stage IV

6.00, (4.90–7.10)

21.00, (17.94–24.06)

ECOG score

0.671

0.504

 PS 0

10.40, (8.95–11.85)

32.50, (27.62–37.38)

 PS 1

9.50, (8.35–10.65)

29.00, (20.18–37.82)

Number of LO

0.000

0.000

  ≤ 2 LO

11.50, (10.02–12.98)

39.00, (29.33–48.67)

  > 2 LO

7.00, (4.65–9.35)

23.00, (20.82–25.18)

Cumulative GTV per patient

0.000

0.000

  ≤ 40 cm³

12.40, (11.31–13.49)

45.95(38.25–53.66)

  > 40 cm³

7.50, (5.77–9.23)

28.30, (20.74–35.86)

System treatments

0.356

0.000

 C + TT

11.20, (10.10–12.30)

40.00, (36.57–43.43)

 C alone

7.50, (4.32–10.68)

28.40, (22.26–34.54)